Targeting Chondroitin Sulfate Glycosaminoglycans to Treat Cardiac Fibrosis in Pathological Remodeling | Zendy

Rongrong Zhao | Zendy; Matthew AckersJohnson | Zendy; Justus Stenzig | Zendy; Chen Chen | Zendy; Tao Ding | Zendy; Yue Zhou | Zendy; Peipei Wang | Zendy; Shi Ling Ng | Zendy; Peter Y. Li | Zendy; Gavin Teo | Zendy; Pauline M. Rudd | Zendy; James W. Fawcett | Zendy; Roger Foo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Targeting Chondroitin Sulfate Glycosaminoglycans to Treat Cardiac Fibrosis in Pathological Remodeling

Author(s) -

Rongrong Zhao,

Matthew AckersJohnson,

Justus Stenzig,

Chen Chen,

Tao Ding,

Yue Zhou,

Peipei Wang,

Shi Ling Ng,

Peter Y. Li,

Gavin Teo,

Pauline M. Rudd,

James W. Fawcett,

Roger Foo

Publication year - 2018

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.117.030353

Subject(s) - medicine , fibrosis , glycosaminoglycan , cardiac function curve , cardiac fibrosis , heart failure , ventricular remodeling , heparan sulfate , immunostaining , mucopolysaccharidosis , endocrinology , pathology , immunohistochemistry , anatomy

Heart failure is a leading cause of mortality and morbidity, and the search for novel therapeutic approaches continues. In the monogenic disease mucopolysaccharidosis VI, loss-of-function mutations in arylsulfatase B lead to myocardial accumulation of chondroitin sulfate (CS) glycosaminoglycans, manifesting as myriad cardiac symptoms. Here, we studied changes in myocardial CS in nonmucopolysaccharidosis failing hearts and assessed its generic role in pathological cardiac remodeling.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research